Skip to main content
main-content

Heart failure

News

09-16-2019 | Heart failure | News

DEFINE-HF: Further support for add-on dapagliflozin as a treatment option for heart failure

Results of the DEFINE-HF trial indicate that add-on dapagliflozin treatment may improve health status among people with established heart failure and reduced ejection fraction.

09-06-2019 | Heart failure | News

Novel risk score stratifies HHF risk in type 2 diabetes

Researchers have developed a novel clinical risk score for hospitalization for heart failure, which identifies people with type 2 diabetes most likely to benefit from sodium-glucose cotransporter 2 inhibition.

09-02-2019 | Heart failure | Highlight | News

Dapagliflozin ‘offers a new approach’ for treating heart failure

The addition of dapagliflozin to standard treatment may be beneficial for patients with established heart failure and reduced ejection fraction, indicate findings from the DAPA-HF trial.

07-18-2019 | Heart failure | Highlight | News

Diabetes-associated heart failure risk greatest in women

Diabetes is a stronger risk factor for heart failure among women compared with men, indicate the results of a large systematic review and meta-analysis.

07-04-2019 | Heart failure | News

Sex difference in HF diabetes impact extended to Asians

Registry data support a larger impact of diabetes on hospitalization and mortality risk in women than men with heart failure.

06-26-2019 | Heart failure | News

Post HF diabetes development increases mortality risk

People who develop diabetes after hospitalization for heart failure have a significantly greater risk for death than people who do not have or develop diabetes, study findings indicate.

06-09-2019 | Type 2 diabetes | ADA 2019 | News

Short-term delays in diabetes onset confer long-term cardioprotective effects

Delaying diabetes onset by at least 6 years in people with impaired glucose tolerance significantly reduces their risk for cardiovascular disease and microvascular complications, show 30-year data from the Da Qing Diabetes Prevention Study.

05-02-2019 | Cardiovascular disorders | News

Metformin may be cardioprotective in patients with coronary artery disease

Findings from the MET-REMODEL trial suggest that metformin treatment may aid regression of left ventricular hypertrophy among nondiabetic patients with coronary artery disease.

04-11-2019 | Empagliflozin | News

EMPRISE shows real-world HF protection with empagliflozin

An interim analysis of EMPRISE shows reductions in heart failure risk with empagliflozin in real-world users that match those reported in the EMPA-REG OUTCOME trial.

03-21-2019 | Heart failure | News

Microvascular disease a marker of heart failure risk in type 2 diabetes

The presence of microvascular disease in people with type 2 diabetes signals a high risk for heart failure, report the EMPA-REG OUTCOME investigators.

03-18-2019 | Dapagliflozin | Highlight | News

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

03-17-2019 | Canagliflozin | News

Canagliflozin may reduce HF events irrespective of ejection fraction

A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.

03-04-2019 | SGLT2 inhibitors | News

Meta-analysis confirms SGLT2 inhibitor heart failure, kidney disease benefits

Sodium-glucose cotransporter-2 inhibitors have a greater effect than glucagon-like peptide-1 receptor agonists on reducing hospitalization for heart failure and kidney disease progression in patients with type 2 diabetes, according to the findings of a systematic review and meta-analysis.

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

09-05-2018 | Heart failure | News

Network meta-analysis backs SGLT2 inhibitors for heart failure prevention

The results of a network meta-analysis offer strong support for use of sodium-glucose cotransporter 2 inhibitors to prevent heart failure (HF) in patients with type 2 diabetes.

07-04-2018 | Heart failure | News

Heart failure particularly high risk in type 1 diabetes patients

The likelihood of dying during or soon after heart failure hospitalization is higher among patients with type 1 than type 2 diabetes, report researchers.

06-08-2018 | Heart failure | News

Established biomarker predicts HF in type 2 diabetes

When levels of N-terminal pro B-type natriuretic peptide are persistently high or rising, patients with type 2 diabetes are at increased risk for being hospitalized with heart failure or dying of cardiovascular causes, research shows.

06-06-2018 | Heart failure | News

Intensive diabetes treatment reduces long-term heart failure risk

Long-term results from the Steno-2 trial show a large reduction in the risk for clinical heart failure among patients with type 2 diabetes who received intensive risk factor control.

03-12-2018 | Canagliflozin | Highlight | News

CANVAS analysis supports SGLT2 inhibitor benefits for HF

The latest analysis of the CANVAS trial indicates that the cardiovascular benefits of canagliflozin in patients with type 2 diabetes may be greatest in those with concomitant heart failure.

03-10-2018 | Heart failure | News

Clinical trial failings leave effect of diabetes medications on HF uncertain

Heart failure is poorly characterized and reported even in cardiovascular outcome trials of glucose-lowering therapies, making it difficult to ascertain the effect of antidiabetic medications on this outcome, say the authors of a systematic review.

11-14-2017 | Canagliflozin | News

Canagliflozin benefits may extend to primary prevention

Further analysis of the CANVAS trial suggests that the benefits of canagliflozin treatment are broadly consistent in type 2 diabetes patients with and without pre-existing cardiovascular disease,

11-13-2017 | Older adults | News

CV complications impact survival in elderly type 2 diabetes patients

Cardiovascular complications, and heart failure in particular, are strongly associated with poor survival in elderly patients with type 2 diabetes, French observational study data show.

10-19-2017 | Vildagliptin | News

Unclear impact of vildagliptin treatment in patients with HF and type 2 diabetes

Results of the VIVIDD trial indicate that it is unclear whether treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin has a beneficial effect on cardiac outcomes among patients with heart failure and type 2 diabetes.

10-18-2017 | Heart failure | News

Glycemic control, drug treatment linked to outcome in patients with HF and type 2 diabetes

Results of a study published in JACC: Heart Failure suggest that glycemic control and drug treatment have complex associations with adverse outcomes among patients with heart failure and type 2 diabetes.

10-11-2017 | Heart failure | News

Sudden death tops CV death causes in type 2 diabetics with atherosclerosis

Sudden death is the most common cause of cardiovascular death among patients with type 2 diabetes and atherosclerotic cardiovascular disease, an analysis of TECOS data shows.

09-22-2017 | Older adults | EASD 2017 | News

Optimizing outcomes: System and patient factors

An EASD session on optimizing patient outcomes included research into the effect of guideline adherence, predictors of changes in medication adherence, and overtreatment of older people with diabetes.

09-14-2017 | SGLT2 inhibitors | EASD 2017 | News

Latest CVD-REAL data bolster cardioprotective effects of SGLT2 inhibition

The CVD-REAL investigators have presented further results demonstrating the effects of sodium-glucose co-transporter 2 inhibitors on cardiovascular outcomes in real-world clinical practice.

09-14-2017 | Heart failure | EASD 2017 | News

Steno-2 shows power of intensive treatment to avert HF

Results from Steno-2 show that intensive multifactorial treatment reduces the risk for heart failure in patients with type 2 diabetes and microalbuminuria.

09-11-2017 | Obesity | News

Metabolically healthy obese concept overturned

A study of 3.5 million people strengthens the evidence against the notion that obesity is only a health risk if people also have metabolic abnormalities.

09-06-2017 | Empagliflozin | News

Empagliflozin improves HF outcomes irrespective of baseline risk

Research shows that treatment with empagliflozin significantly reduces the risk for heart failure hospitalization and cardiovascular disease death among patients with type 2 diabetes, even if their baseline risk is relatively low.

06-14-2017 | Canagliflozin | ADA 2017 | News

Integrated CANVAS: canagliflozin offers cardioprotection at amputation cost

The integrated results of the CANVAS and CANVAS-R studies show that canagliflozin reduces the risk for cardiovascular and renal events in patients with type 2 diabetes at high cardiovascular risk.

03-20-2017 | SGLT2 inhibitors | News

CVD-REAL extends EMPA-REG findings to real-world patients

Findings from the CVD-REAL trial show a protective effect of sodium glucose cotransporter-2 inhibitors against heart failure in real-world patients with type 2 diabetes.

03-18-2017 | Heart failure | News

Neprilysin inhibition could improve glycemic control in diabetic HF patients

A post-hoc analysis of the PARADIGM-HF trial suggests that the inclusion of a neprilysin inhibitor in the medication of patients with heart failure and diabetes might enhance glycemic control.

Image Credits